Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst
Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst
Needham initiated coverage on Praxis Precision Medicines Inc (NASDAQ:PRAX), a clinical-stage biopharmaceutical company, engaged in the development of therapies for central nervous system disorders.
Needham對Praxis Precision Medicines Inc (NASDAQ:PRAX)，一家從事中樞神經系統疾病治療方案開發的臨床生物製藥公司，進行了覆蓋。
The company's lead product ulixacaltamide for essential tremor (ET) is undergoing Essential3 Phase 3 program, with topline results expected in the second half of 2024 to support a planned New Drug Application (NDA) submission in 2025.
該公司的首款針對重要震顫病（ET）的主打產品ulixacaltamide正在進行Essential3第三階段計劃，預計在2024年下半年公佈最終結果，以支持計劃在2025年提交新藥申請（NDA）。
- The analyst writes that sales of Ulixa for essential tremor (ET), if successful in Phase 3, could peak at over $1 billion in 2030 (60% probability of success).
- Needham writes, "value of ulixacaltamide in essential tremor alone is underappreciated at current levels."
- 分析師寫道，如果Essential3第三階段成功，針對重要震顫病（ET）的Ulixa的銷售額可能在2030年達到10億美元以上（成功的概率爲60%）。
- Needham表示，ulixacaltamide在重要震顫病中的價值在當前水平下被低估。
The analyst initiates with a Buy rating and a price target of $145.
該分析師發起了買入評級，給出了145美元的目標價位。
The company's second program is PRAX-628 for Focal Onset Seizures.
該公司的第二個項目是PRAX-628，針對局竈性發作性癲癇。
- Praxis plans to initiate two efficacy studies in focal onset seizures. The first study is expected to begin in the second half of 2024, with topline results expected in 2025, and the second study is expected to initiate in the first half of 2025, with topline results expected in the first half of 2026.
- Praxis計劃啓動兩項針對局竈性發作性癲癇的有效性研究。第一項研究預計於2024年下半年開始，最終結果預計在2025年公佈。第二項研究預計於2025年上半年開始，最終結果預計在2026年上半年公佈。
Praxis anticipates topline results from the Phase 2 EMBOLD study of PRAX-562 for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) in the third quarter of 2024.
Praxis預計在2024年第三季度公佈PRAX-562治療SCN2A和SCN8A發育性和癲癇性腦病（DEEs）的II期EMBOLD研究的最終結果。
Praxis is completing multiple global regulatory interactions in the first half of 2024 in anticipation of starting the pivotal phase of the program later in 2024 for Elsunersen (PRAX-222) for SCN2A Gain-of-Function DEEs.
Praxis於2024年上半年完成了多個全球性監管部門的交互，並有望在2024年晚些時候開始該計劃的關鍵階段，該計劃旨在治療SCN2A增效型DEEs的Elsunersen（PRAX-222）。
PRAX-628 in focal epilepsy and elsunersen in SCN2A GoF could drive more than $1.5 billion in peak sales, with an upside from label expansion.
PRAX-628治療局竈性癲癇和SCN2A增效型DEEs的Elsunersen可能帶來超過15億美元的銷售額，並具有標籤擴展的潛力。
Praxis' cash runway into 2027 and an early pipeline across the Cerebrum and Solidus platforms can potentially generate significant long-term value.
Praxis的現金儲備可以支持公司運營到2027年，並且具有Cerebrum和Solidus平台上的早期管線，這可能產生顯着的長期價值。
Needham adds that positive data from Ulixa Phase 3 and POC for PRAX-562 in the third quarter should continue to drive momentum in Praxis stock.
Needham補充說，第三季度Ulixa第三階段和PRAX-562 POC的積極數據應繼續推動Praxis股票的動力。
Price Action: PRAX shares are down 3.44% at $40.27 at the last check on Monday.
股票價格：截至星期一的最後一次檢查，PRAX股價下跌了3.44%，降至40.27美元。
Photo by PublicDomainPictures from Pixabay
圖片由Pixabay的PublicDomainPictures提供
譯文內容由第三人軟體翻譯。